HBK Sorce Advisory’s CRISPR Therapeutics CRSP Stock Holding History

HBK Sorce Advisory’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,862	Closed	-$208K	–	603
2021 Q3	$208K	Buy	1,862 +45	+2%	+$5.65K	0.01%	547
2021 Q2	$294K	Buy	1,817 +140	+8%	+$17K	0.02%	449
2021 Q1	$204K	Buy	+1,677	New	+$253K	0.01%	509
2019 Q2	–	Sell	-6,530	Closed	-$233K	–	417
2019 Q1	$233K	Buy	+6,530	New	+$226K	0.02%	378
2018 Q4	–	Sell	-6,569	Closed	-$291K	–	391
2018 Q3	$291K	Sell	6,569 -760	-10%	-$39.8K	0.03%	302
2018 Q2	$431K	Buy	7,329 +2,418	+49%	+$138K	0.05%	248
2018 Q1	$224K	Buy	+4,911	New	+$203K	0.03%	334

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

HBK Sorce Advisory's CRSP Position: Q4 2021 in Review

HBK Sorce Advisory sold out of CRISPR Therapeutics (CRSP) in Q4 2021, closing a stake of 1,862 shares — an estimated $208K sold.

HBK Sorce Advisory first reported a position in CRSP in Q1 2018 and held it in 7 quarters. The position peaked at $431K in Q2 2018. 446 funds tracked by Wall St. Rank hold CRSP as of Q4 2021.

HBK Sorce Advisory reported no remaining CRISPR Therapeutics position as of Q4 2021 after selling out during the quarter.
HBK Sorce Advisory sold 1,862 CRISPR Therapeutics shares in Q4 2021, an estimated $208K.
HBK Sorce Advisory first reported a position in CRISPR Therapeutics in Q1 2018 and held it in 7 quarters.
HBK Sorce Advisory's CRISPR Therapeutics position peaked at $431K in Q2 2018.
446 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2021.

Based on HBK Sorce Advisory's 13F filing for Q4 2021, filed 15 Feb 2022.